Metabolic biomarkers and personalized medicine are two of the fastest growing segments of the biomedical industry; hepcidin is useful for both applications.

We anticipate that the benefits of a hepcidin biomarker will range far beyond the current indications. We are interested in working with researchers and clinicians to explore specific conditions where our assay may be useful for early detection, diagnosis, patient stratification or management of therapy.

We are also developing new antibodies and multiplex assays which support research and preclinical evaluations in nonhuman models.

Our team has a history of innovation, technical and clinical leadership, meeting objectives and successful partnering. We welcome opportunities to collaborate with you whether in small highly targeted studies or in a broader strategic alliance.